Study of AR-13324 in Patients With Elevated Intraocular Pressure

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002

Ocular Hypertension Open Angle Glaucoma

COMPLETED PHASE2

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491

Ocular Hypertension Open-angle Glaucoma

COMPLETED PHASE3

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200

Elevated Intraocular Pressure

COMPLETED PHASE2

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579

Glaucoma

COMPLETED PHASE2

Ocular Hypotensive Efficacy of AR-102

NCT00523250

Glaucoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Hypertension Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AR-13324 Ophthalmic Solution 0.01%

1 drop to study eye once daily

Group Type EXPERIMENTAL

AR-13324 Ophthalmic Solution 0.01%

Intervention Type DRUG

Administered to study eye, once daily (QD) in the morning (AM) for 7 days

AR-13324 Ophthalmic Solution 0.02%

1 drop to study eye once daily

Group Type EXPERIMENTAL

AR-13324 Ophthalmic Solution 0.02%

Intervention Type DRUG

Administered to study eye, QD AM for 7 days

AR-13324 Ophthalmic Solution 0.04%

1 drop to study eye once daily

Group Type EXPERIMENTAL

AR-13324 Ophthalmic Solution 0.04%

Intervention Type DRUG

Administered to study eye, QD AM for 7 days

AR-13324 Ophthalmic Solution Vehicle

1 drop to study eye once daily

Group Type PLACEBO_COMPARATOR

AR-13324 Ophthalmic Solution Vehicle

Intervention Type OTHER

Administered to study eye, QD AM for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AR-13324 Ophthalmic Solution 0.01%

Administered to study eye, once daily (QD) in the morning (AM) for 7 days

Intervention Type DRUG

AR-13324 Ophthalmic Solution 0.02%

Administered to study eye, QD AM for 7 days

Intervention Type DRUG

AR-13324 Ophthalmic Solution 0.04%

Administered to study eye, QD AM for 7 days

Intervention Type DRUG

AR-13324 Ophthalmic Solution Vehicle

Administered to study eye, QD AM for 7 days

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Netarsudil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or greater. 18 years of age or greater.
2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
3. Unmedicated (post-washout, p.r.n.) IOP ≥ 24 mm Hg in one or both eyes at 08:00 hours, ≥ 21 mm Hg at 10:00, 12:00 and 16:00 hours on post-washout measurement (Visit 1).
4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
5. Able and willing to give signed informed consent and follow study instructions.

Exclusion Criteria

Ophthalmic: Either eye

1. Intraocular pressure \> 36 mm Hg
2. Known hypersensitivity to any component of the formulation or to topical anesthetics, (benzalkonium chloride, etc.)
3. Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
4. Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 1), or history of herpes simplex keratitis.
5. Contact lens wear within 30 minutes of instillation of study medication.
6. Ocular medication of any kind within 30 days of Visit 2, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 2) or c) lubricating drops for dry eye (which may be used throughout the study),
7. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (e.g., advanced glaucomatous optic nerve head or visual field loss).
8. Any abnormality preventing reliable applanation tonometry in either eye. Study eye:
9. Glaucoma: pseudoexfoliation or pigment dispersion component, history of acute angle-closure glaucoma, or closed or narrow angle upon gonioscopy. Note: Previous laser peripheral iridotomy is NOT acceptable.
10. Previous glaucoma intraocular surgery or laser procedures such as argon laser trabeculoplasty (ALT), selective laser trabeculoplasty (SLT) or micropulse laser trabeculoplasty ( MLT), as well as refractive procedures such as radio keratotomy (RK), laser eye surgery (LASIK), photorefractive keratectomy (PRK), or collagen cross linking.
11. Central corneal thickness greater than 600 μm.

General/Systemic:
12. Clinically significant abnormalities in laboratory tests at screening, recognizing that subjects are not fasting at the time of drawing blood.
13. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
14. Participation in any investigational study within the past 30 days.
15. Changes of systemic medication during the study that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
16. Due to status of preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No